Examining Side Effects of the Sputnik V COVID-19 Vaccine Side effects of Sputnik V vaccine
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 12 No. 4 (2022),
16 October 2022
,
Page 38573
https://doi.org/10.32598/ijmtfm.v12i4.38573
Abstract
Background: As a result of the COVID-19 pandemic, many vaccines were developed to counter the disease, including the vector-based Sputnik V vaccine. This study aims to identify the side effects of the Sputnik V COVID–19 vaccine in a medical center and compare the results with the previous reports.
Methods: A questionnaire-based study was performed after the injection of the first and second doses of the vaccine to assess the side effects experienced by the participants. It was performed by reviewing similar previous studies.
Results: Injection site pain, muscle pain, fever, fatigue, chills, and headache were the most common side effects of the vaccine. The incidence of major side effects decreased with age and was lower in men. In our study and others, the incidence of side effects was decreased in the second dose. In some studies, participants with a previous history of Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCOV-2) infection developed more side effects, especially injection site pain, muscle pain, and fatigue.
Conclusion: Most studies agree with our reported results. Serious side effects of this vaccine are rare and may be considered tolerable in adults.
- Side effects
- COVID-19
- Gam-COVID-Vac vaccine
- Sputnik V
- COVID-19 Vaccines
- Severe acute respiratory syndrome coronavirus 2 (SARSCOV-2)
How to Cite
References
World Health Organisation(WHO). WHO coronavirus disease(covid-19) dashboard. Geneva: World Health Organisation; 2022. [Link]
World Health Organisation(WHO). The different types of covid-19 vaccines. Geneva: World Health Organisation; 2022. [Link]
World Health Organisation(WHO). Side effects of covid-19 vaccines. Geneva: World Health Organisation; 2022. [Link]
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rad26 and rad5 vector-based heterologous prime-boost covid-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021; 397(10275):671-81. [DOI:10.1016/S0140-6736(21)00234-8] [PMID] [PMCID]
Pagotto V, Ferloni A, Mercedes Soriano M, Díaz M, Braguinsky Golde N, González MI, et al. Active monitoring of early safety of sputnik v vaccine in Buenos Aires, Argentina. Medicina(B Aires). 2021; 81(3):408-14. [PMID]
Jarynowski A, Semenov A, Kamiński M, Belik V. Mild adverse events of sputnik v vaccine in Russia: Social media content analysis of telegram via deep learning. Journal of Medical Internet Research. 2021; 23(11):e30529. [DOI:10.2196/30529] [PMID] [PMCID]
Zare H, Rezapour H, Mahmoodzadeh S, Fereidouni M. Prevalence of covid-19 vaccines(sputnik v, azd-1222, and covaxin) side effects among healthcare workers in Birjand city, Iran. International Immunopharmacology. 2021; 101(Pt B):108351. [DOI:10.1016/j.intimp.2021.108351] [PMID] [PMCID]
Montalti M, Soldà G, Di Valerio Z, Salussolia A, Lenzi J, Forcellini M, et al. Rocca Observational study: Early results on safety of sputnik v vaccine(gam-covid-vac) in the Republic of San Marino using active surveillance. EClinicalMedicine. 2021; 38:101027. [DOI:10.1016/j.eclinm.2021.101027] [PMID] [PMCID]
Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored covid-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet. 2020; 395(10240):1845-54. [DOI:10.1016/S0140-6736(20)31208-3]
Babamahmoodi F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Mousavi SA, Ovaise G, et al. Side effects and Immunogenicity following administration of the Sputnik v covid-19 vaccine in health care workers in Iran. Scientific Reports. 2021; 11(1):21464. [DOI:10.1038/s41598-021-00963-7] [PMID] [PMCID]
Houshmand B, Keyhan SO, Fallahi HR, Ramezanzade S, Sadeghi E, Yousefi P. Vaccine-associated complications: A comparative multicenter evaluation among dental practitioners and dental students-which candidate vaccine is more safe in sars cov ii, gam-covid-vac(sputnik v), chadox1 ncov-19(astrazeneca), bbv152(covaxin), or bbibp-corv(sinopharm)? Maxillofacial Plastic and Reconstructive Surgery. 2022; 44(1):3. [DOI:10.1186/s40902-021-00330-6] [PMID] [PMCID]
Sun Q, Fathy R, McMahon DE, Freeman EE. Covid-19 vaccines and the skin: The landscape of cutaneous vaccine reactions worldwide. Dermatologic Clinics. 2021; 39(4):653-73. [DOI:10.1016/j.det.2021.05.016] [PMID] [PMCID]
- Abstract Viewed: 545 times
- pdf Downloaded: 213 times